CN101413019B - Preparation of casein glycomacmpepride - Google Patents
Preparation of casein glycomacmpepride Download PDFInfo
- Publication number
- CN101413019B CN101413019B CN2008101623396A CN200810162339A CN101413019B CN 101413019 B CN101413019 B CN 101413019B CN 2008101623396 A CN2008101623396 A CN 2008101623396A CN 200810162339 A CN200810162339 A CN 200810162339A CN 101413019 B CN101413019 B CN 101413019B
- Authority
- CN
- China
- Prior art keywords
- casein
- enzyme
- acid
- cmp
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 235000021240 caseins Nutrition 0.000 title claims abstract description 32
- 239000005018 casein Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims description 9
- 108090000790 Enzymes Proteins 0.000 claims abstract description 32
- 102000004190 Enzymes Human genes 0.000 claims abstract description 32
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 24
- 239000012530 fluid Substances 0.000 claims abstract description 21
- 239000012528 membrane Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- 229920002492 poly(sulfone) Polymers 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 239000006228 supernatant Substances 0.000 claims abstract description 7
- 239000008367 deionised water Substances 0.000 claims abstract description 6
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 6
- 238000009413 insulation Methods 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000872 buffer Substances 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims description 18
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 14
- 210000002784 stomach Anatomy 0.000 claims description 13
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 9
- 238000013016 damping Methods 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 230000005611 electricity Effects 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 claims description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
- 239000002953 phosphate buffered saline Substances 0.000 claims description 3
- 108010076119 Caseins Proteins 0.000 abstract description 26
- 238000000926 separation method Methods 0.000 abstract description 10
- 239000002994 raw material Substances 0.000 abstract description 6
- 238000003916 acid precipitation Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 108010067454 caseinomacropeptide Proteins 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 238000005119 centrifugation Methods 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 102000011632 Caseins Human genes 0.000 description 24
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 18
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 9
- 102000007544 Whey Proteins Human genes 0.000 description 8
- 108010046377 Whey Proteins Proteins 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 5
- 239000005862 Whey Substances 0.000 description 5
- 230000001804 emulsifying effect Effects 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 229940060155 neuac Drugs 0.000 description 5
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- IKRZCYCTPYDXML-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;hydrochloride Chemical compound Cl.OC(=O)CC(O)(C(O)=O)CC(O)=O IKRZCYCTPYDXML-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 229940021722 caseins Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- -1 N-acetylneuraminyl Chemical group 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- TYYLDKGBCJGJGW-WMZOPIPTSA-N Trp-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=C(O)C=C1 TYYLDKGBCJGJGW-WMZOPIPTSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000000937 glycosyl acceptor Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention provides a method for preparing casein glycomacropeptide, which comprises the following steps: casein is dissolved into a buffer liquid with the pH value of between 2.0 and 7.6, enzyme is added to enzymolyze for 2 to 5 hours at a temperature of between 30 and 37 DEG C, then the mixture is quickly cooled to between 0 and 4 DEG C, the pH value is adjusted to between 4.5 and 4.8 with inorganic acid, the thermal insulation acid precipitation is performed for 5 to 10 hours at a temperature of between 0 and 4 DEG C; a supernatant fluid is subjected to ultrafiltration concentration by a polysulphone membrane with the average molecular weight cutoff of between 3,000 and 5,000 after the centrifugation to obtain a concentrated solution 1; the concentrated solution 1 is diluted by deionized water and then continues to be ultrafiltered by the polysulphone membrane with the average molecular weight cutoff of between 3,000 and 5,000, the operation is repeated for a few times until theelectric conductance of an effluent liquid is less than 500mscm<-1>; and a trapped fluid is subjected to ultrafiltration concentration by a polysulphone membrane with the average molecular weight cutoff of between 30,000 and 100,000 to obtain a concentrated solution 2, and the concentrated solution 2 is dried to obtain the casein glycomacropeptide. The method has the advantages that the method takes the casein as a raw material to specifically and limitedly hydrolyze to release CMP under the action of pepsine and/or trypsinase, then adopts the acid precipitation for preliminary separation, combines membrane ultrafiltration to realize the CMP separation with higher purity, has simple process and easy operation, and is suitable for industrialized production.
Description
(1) technical field
The present invention relates to a kind of preparation method of casein PROVON 190.
(2) background technology
CMP is meant carbon teminal fragment solubility, that be rich in sugar chain that rennin degraded κ-casein 105-106,169-170 peptide bond produce, and molecule is made of 64 amino-acid residues, is rich in glycosyl and phosphate.CMP content is only second to lactoglobulin and opalescin in the whey, accounts for 20～30% of whey total protein.
The amino acid that CMP is special is formed the glycosylation of height and nutritive property, physiologically active and the physico-chemical property that phosphorylation has been given the many uniquenesses of CMP.CMP does not contain die aromatischen Aminosaeuren, and (Phe, Trp Tyr), do not contain Cys yet, and a methionine(Met) is only arranged.The iso-electric point of this acidity peptide between 4～5, the solubleness height, thermostability is strong.Topmost glycosylation site is mainly Thr 121, and Thr 131, Thr133, and Thr 136 (variantA), Thr 142, and Thr 165, and Thr 135, and Ser 141 and Ser 142 are potential glycosylation sites.Three phosphorylation sites are respectively Ser 149, and Ser 127.The glycosylation form accounts for 50% of total CMP, is called PROVON 190 glycomacropeptide (GMP).Five kinds of sugar chains that link to each other with sialic acid are respectively by N-acetylneuraminyl (NeuAc), galactosyl (Gal), and N-acetylgalactosamine (Gal-NAc) forms.Monose: GalNAc-O-R (0.8%); Disaccharides: Gal β 1 → 3 GalNAc-O-R (6.3%); Trisaccharide: NeuAc α 2 → 3 Gal β, 1 → 3GalNAc-O-R (18.4%), trisaccharide: Gal β 1 → 3 (NeuAc α 2 → 6) GalNAc-O-R (18.5%); Tetrose NeuAc α 2 → 3 Gal β 1 → 3 (NeuAc α 2 → 6) GalNAc-O-R (56%).The branched-amino acid content is abundant and Met content is low among the CMP, and these meals that are fit to very much the liver problem sufferer are formed.CMP does not contain Phe, therefore can be used as phenylketonuria patient's diet composition, but Thr content height might cause high threonine disease.Additional CMP also can increase the absorption of Zn.Sialic acid among the CMP also is crucial to its biological activity in addition.Interior animal experiment shows that external source supply sialic acid can increase the ganglioside in the brain, improves learning capacity.This effect realizes by meals CMP probably.
Because high glycosylation, the glycosyl acceptor of CMP can be discerned many pathogenic agent, and extracellular toxin plays sanatory effect.Can effectively avoid influenza infection as CMP in conjunction with Toxins,exo-, cholera, protection cell.CMP also can suppress the carious tooth bacterium and (as Streptococcus mutans, S.sanguis) sticking and regulate plaque microbiological and form in the oral cavity, play the preventing dental caries effect.
CMP also can realize the immunomodulatory effect by suppressing the effect of phytokinin inductive lymphopoiesis, CMP even can induce that specific lymphocyte is tricky dies.These immunomodulatory effects are mainly based on polypeptide and two aspects of sialic acid.Newborn Mammals experimental study shows that meals CMP obviously suppresses the production vigor of Ig G antibody, helps to reduce the immunne response that antigen causes.Someone advises CMP is applied to immunosuppression food or enteritis case control.The existence of N-n acetylneuraminic acid n can promote Bifidobacterium B.breve among the CMP in addition, B.bifidum, and B.infantis microbial growth, the effect of this nutrition intestinal microecology makes CMP potential as the use of the prebiotics in the functional food, also can be used as the profitable strain effect in the supplement simulation breast milk in the infant formula.In addition, the CMP that contains the N-n acetylneuraminic acid n can regulate food intake and gastrointestinal function by stimulating intestinal receptor to discharge cholecystokinin.
CMP has the functional property of many uniquenesses in addition, and the researchist is with keen interest to it being developed to the novel food with health-promoting effect.CMP is the molten macromole of highly-hydrophilic, electronegative (even under low pH condition).CMP solubleness is minimum in pH value 1～5 scope, but temperature influence not.CMP another one key property is exactly the good emulsifying characteristic.Emulsifying capacity is the strongest under the alkaline condition, pH 4.5～5.5 emulsifying power minimums.The thermostability of CMP makes that its emulsifying effect is more lasting, especially in neutral and alkaline pH scope.Emulsifying stability under this alkaline condition makes especially have advantage in the wide food of some processing pH variation range of CMP.In addition, also relevant for the report of the higher foaminess of CMP.
Based on many physiologically actives, nutritive property and functional property, CMP is having been widely used aspect food, healthcare products, medicine, the daily chemical products.At present about the preparation isolation technique of CMP, mainly contain two classes: a class is based on that CMP forms non-covalent bonded polymer, the dissociated character of acidic conditions under the neutrallty condition, adopts ultra-filtration and separation.This method technology is simple, easy to operate, but owing to have the beta-lactoglobulin (MW18KDa) and the ALA (MW12KDa) of high level in the whey, its molecular weight and CMP monomer (MW6～7KDa), the CMP tetramer (MW25～30KDa) close, so the selectivity of ultra-filtration and separation is not high.EP0453782 at first adopts flocculence to remove foreign protein, and the ultrafiltration clear liquid has partly solved foregoing problems then, but the liquid ethanol sedimentation that dams may have certain influence to the quality of CMP product.WO 94/15952 utilizes the thermostability of CMP, and thermal treatment makes that the complete sex change of other whey-protein is centrifugal then removes, and obtains CMP solution.Degeneration methods separates thoroughly, quality product is better, but whey-protein is because the sex change functional property is greatly affected quality deterioration.And aforesaid method is raw material separation of C MP with cheese whey (whey-protein) mainly, and this belongs to the utilization of cheese by product abroad, has resources advantage.Therefore but China's whey resource is comparatively limited, carries out the approach that casein specific enzymes hydrolyzing, separating is equipped with CMP and tallies with the national condition.Chromatographic separation technology in recent years is as hydrophobic chromatography, ion-exchange chromatography (EP 0 488589) gel filtration chromatography] technical progress is very fast, for separation purifying technique provides new selection, and good separation, but the separating medium costliness is separated small scale.The preparation of domestic existing a small amount of CMP separates report, mainly be with the casein be raw material to adopt the proteolytic cleavage mode to prepare with antibiotic be the wide spectrum casein peptide of target, but hydrolysising condition is extreme, specificity is not high, therefore yield is not high, and the product purification procedures is loaded down with trivial details, is difficult to industrialization.
(3) summary of the invention
The object of the invention provides in a kind of product that the assorted peptide content of small molecules is few, purifying convenient, and the preparation method of simple, the easy to operate casein PROVON 190 of technology.
The technical solution used in the present invention is:
A kind of preparation method of casein PROVON 190, described method comprises:
(1) casein is dissolved in the damping fluid of pH2.0～7.6, add enzyme in 30～37 ℃ of enzymolysis 2～5 hours, described enzyme is stomach en-, trypsinase or stomach en-and tryptic mixed enzyme, described enzyme add-on with enzyme live (during mixed enzyme with total enzyme work) count 400～800IU/g casein;
(2) enzymolysis finishes postcooling to 0～4 ℃, and transferring pH with mineral acid is 4.5～4.8, and in heavy 5～10 hours of 0～4 ℃ of insulation acid, centrifugal, get supernatant liquor and carry out next step operation; Described mineral acid is hydrochloric acid, trichoroacetic acid(TCA) or perchloric acid, is preferably perchloric acid;
(3) supernatant liquor is 3000～5000 polysulfone membrane ultrafiltration and concentration with average molecular weight cut-off, obtain concentrating that trapped fluid 1 continues with average molecular weight cut-off with deionized water dilution back is 3000～5000 polysulfone membrane ultrafiltration, repeat repeatedly to lead less than 500mscm until the effluent liquid electricity
-1, obtain the polysulfone membrane ultrafiltration and concentration of concentrated solution with average molecular weight cut-off 30000～100000, obtain concentrating trapped fluid 2 dryings and obtain described casein PROVON 190.
Described damping fluid can be this area damping fluid commonly used, is preferably the phosphate buffered saline buffer of pH6.6～7.6 or the hydrochloric acid-citrate buffer solution of pH2.0～3.0 among the present invention.
Used enzyme is stomach en-and tryptic mixed enzyme, and the ratio of described stomach en-and trypsinase consumption is 2:1 with enzyme work, and described enzyme dosage is the 500IU/g casein with total enzyme work.
Described casein starting point concentration is 10～100g/L damping fluid, is preferably the 50g/L damping fluid.
Drying is spraying drying or lyophilize in the described step (3).
Preferably, described method is as follows:
(1) casein is dissolved in the phosphate buffered saline buffer of pH6.6, described casein starting point concentration is the 50g/L damping fluid, add enzyme in 37 ℃ of enzymolysis 2～5 hours, described enzyme is stomach en-, trypsinase or stomach en-and the work of the trypsinase enzyme mixed enzyme than 2:1, and described enzyme add-on is the 500IU/g casein with total enzyme work;
(2) enzymolysis finishes postcooling to-4 ℃, and transferring pH with perchloric acid is 4.6, and in heavy 5～10 hours of-4 ℃ of insulation acid, centrifugal, get supernatant liquor and carry out next step operation;
(3) supernatant liquor is 5000 polysulfone membrane ultrafiltration and concentration with average molecular weight cut-off, and obtaining that trapped fluid 1 continues with average molecular weight cut-off with deionized water dilution back is 5000 polysulfone membrane ultrafiltration, repeats repeatedly to lead less than 500mscm until the effluent liquid electricity
-1, obtain the polysulfone membrane ultrafiltration and concentration of concentrated solution with average molecular weight cut-off 30000, obtain trapped fluid 2 dryings and obtain described casein PROVON 190.
It is raw material that the present invention adopts casein, adopts suitable zymin limited hydrolysis, realizes caseic specificity hydrolysis, and small-molecular peptides content is few in the product, and purifying is convenient; Acid precipitation binding film isolation technique is adopted in separation and purification, has that technology is simple, separation efficiency is high, is easy to advantages such as suitability for industrialized production, and the CMP product purity that obtains is higher, steady quality.
Beneficial effect of the present invention is mainly reflected in: the present invention is that raw material adopts stomach en-and/or trypsinase specificity, limited hydrolysis to discharge CMP under nearly neutrallty condition with the casein, adopt the Acid precipitation initial gross separation then, the binding film ultrafiltration realizes that the CMP of higher degree separates, productive rate, purity are all higher, and technology is simple, easy handling, suitability for industrialized production.
(4) embodiment
The present invention is described further below in conjunction with specific embodiment, but protection scope of the present invention is not limited in this:
Embodiment 1:
100 gram caseins (Suo Laibao Science and Technology Ltd.) are dissolved in the 0.1M phosphate buffer soln (pH6.6) and are settled to 2 liters, 37 ℃ of water-baths, add 2.5 gram stomach en-s (vigor 20000IU/g), enzyme work/substrate is than being the 500I.U/g casein, behind the hydrolysis 3h, be cooled to 0～4 ℃ immediately, transfer pH to 4.6 with 6M perchloric acid, 4 ℃ of heavy 8h of insulation acid, the centrifugal 15min of 5000r/m gets clear liquid, polysulfone membrane (PXB005A50 with average molecular weight cut-off 5KDa, U.S. Mi Libo company) ultrafiltration and concentration, deionized water dilution trapped fluid to original volume is used the polysulfone membrane ultrafiltration of average molecular weight cut-off 5KDa again, leads less than 500mscm until the effluent liquid electricity
-1Trapped fluid is with 20 times of the polysulfone membrane ultrafiltration and concentration of the molecular weight 30KDa that on average dams, and concentrated solution spraying drying or lyophilize get CMP powder (sample A), and analysing protein content, sialic acid content calculate productive rate.
Embodiment 2:
Operation is substantially with example 1, and difference finally obtains the CMP product and is designated as B for the heavy used mineral acid of acid is a 6M hydrochloric acid, and analysing protein content, sialic acid content calculate productive rate.
Embodiment 3:
Operation is substantially with example 1, and difference finally obtains CMP and is designated as C for the heavy used mineral acid of acid is the 6M trichoroacetic acid(TCA), and analysing protein content, sialic acid content calculate productive rate.
Embodiment 4:
Operation is substantially with example 1, and difference is that the used buffered soln of solubilising casein is 0.1M hydrochloric acid-citric acid solution (pH 2.0), and hydrolysis pH is 2.0, transfers pH 4.6 with 6M NaOH when acid is heavy.Finally obtain CMP and be designated as D, analysing protein content, sialic acid content calculate productive rate.
Embodiment 5:
Operation is substantially with example 1, difference is that used enzyme preparation is 6.250g trypsin vigor 8000IU/g), the used buffered soln of solubilising casein is 0.1M phosphate buffer soln (pH7.6), hydrolysis pH is 7.6, finally obtain CMP and be designated as E, analysing protein content, sialic acid content calculate productive rate.
Embodiment 6:
100 gram caseins are dissolved in the 0.1M phosphate buffer soln (pH 6.6) and are settled to 2 liters, and 37 ℃ of water-baths add 1.667g stomach en-(vigor 20000IU/g), 2.083g trypsin vigor 8000IU/g).Behind the hydrolysis 3h, be cooled to 0～4 ℃ immediately, transfer pH to 4.6 with 6M perchloric acid, 4 ℃ of heavy 8h of insulation acid, the centrifugal 15min of 5000r/m gets clear liquid, with polysulfone membrane (the U.S. Mi Libo company) ultrafiltration and concentration of average molecular weight cut-off 5000, deionized water dilution trapped fluid is led the cm less than 500ms to original volume ultrafiltration again until the effluent liquid electricity
-1. the trapped fluid polysulfone membrane ultrafiltration and concentration of the molecular weight 30KDa that on average dams, concentrated solution spraying drying or lyophilize get CMP powder (sample F), and analysing protein content, sialic acid content calculate productive rate.
Embodiment 7:
Operation is substantially with example 6, and difference is that second section used polysulfone membrane of ultrafiltration molecular weight that on average dams is 50KDa, finally obtains the CMP powder and is designated as G, and analysing protein content, sialic acid content calculate productive rate.
Embodiment 8:
Operation is substantially with example 6, and difference is that second section used polysulfone membrane of ultrafiltration molecular weight that on average dams is 100KDa (U.S. Mi Libo company), finally obtains the CMP powder and is designated as H, and analysing protein content, sialic acid content calculate productive rate.
The CMP composition that each embodiment makes sees Table 1.
Table 1: different methods prepares the composition of gained CMP
| Project (%) | The total N of protein content * 6.38 | Sialic acid content | Purity | Productive rate |
| A | 90.6 | 3.8 | 87.6 | 9.24 |
| B | 90.8 | 3.3 | 85.2 | 8.76 |
| C | 88.3 | 3.4 | 86.6 | 9.05 |
| D | 89.2 | 3.1 | 75.6 | 7.24 |
| E | 89.4 | 4.0 | 88.2 | 8.98 |
| F | 88.9 | 4.5 | 92.4 | 10.2 |
| G | 91.5 | 4.3 | 92.0 | 8.66 |
| H | 92.0 | 4.2 | 91.6 | 7.24 |
Annotate: productive rate is that CMP accounts for the caseic mass percent of raw material.
Claims (6)
1. the preparation method of a casein PROVON 190, described method comprises:
(1) casein is dissolved in the damping fluid of pH2.0～7.6, add enzyme in 30～37 ℃ of enzymolysis 2～5 hours, described enzyme is stomach en-, trypsinase or stomach en-and tryptic mixed enzyme, and described enzyme add-on is 400～800IU/g casein with enzyme work;
(2) enzymolysis finishes postcooling to 0～4 ℃, and transferring pH with acid is 4.5～4.8, and in heavy 5～10 hours of 0～4 ℃ of insulation acid, centrifugal, get supernatant liquor and carry out next step operation; Described acid is hydrochloric acid, trichoroacetic acid(TCA) or perchloric acid;
(3) supernatant liquor is 3000～5000 polysulfone membrane ultrafiltration and concentration with average molecular weight cut-off, and obtaining that trapped fluid 1 continues with average molecular weight cut-off with deionized water dilution back is 3000～5000 polysulfone membrane ultrafiltration, repeats repeatedly to lead less than 500mscm until the effluent liquid electricity
-1, obtain the polysulfone membrane ultrafiltration and concentration of concentrated solution with average molecular weight cut-off 30000～100000, obtain trapped fluid 2 dryings and obtain described casein PROVON 190.
2. the method for claim 1 is characterized in that described damping fluid is the phosphate buffered saline buffer of pH6.6～7.6.
3. the method for claim 1, it is characterized in that used enzyme is stomach en-and tryptic mixed enzyme in the described step (1), the ratio of described stomach en-and trypsinase consumption is 2: 1 with enzyme work, and described enzyme dosage is the 500IU/g casein with total enzyme work.
4. the method for claim 1 is characterized in that described casein starting point concentration is the 50g/L damping fluid.
5. the method for claim 1 is characterized in that used acid is perchloric acid in the described step (2).
6. the method for claim 1 is characterized in that dry described in the described step (3) is spraying drying or lyophilize.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101623396A CN101413019B (en) | 2008-11-22 | 2008-11-22 | Preparation of casein glycomacmpepride |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101623396A CN101413019B (en) | 2008-11-22 | 2008-11-22 | Preparation of casein glycomacmpepride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101413019A CN101413019A (en) | 2009-04-22 |
| CN101413019B true CN101413019B (en) | 2011-08-31 |
Family
ID=40593757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101623396A Expired - Fee Related CN101413019B (en) | 2008-11-22 | 2008-11-22 | Preparation of casein glycomacmpepride |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101413019B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102399282A (en) * | 2010-09-10 | 2012-04-04 | 天津科技大学 | Casein glycomacropeptide and its preparation method |
| CN102296100A (en) * | 2011-09-09 | 2011-12-28 | 江南大学 | Preparation method of casein antihypertensive peptides |
| CN104041597B (en) * | 2014-06-24 | 2017-01-11 | 黑龙江省乳品工业技术开发中心 | Preparation method for formula milk powder with high oxidization resistance |
| CN107484939B (en) * | 2017-03-20 | 2021-05-07 | 浙江工商大学 | Preparation method and application of casein-carboxylated chitosan self-assembled nano microcapsule |
| EP4008190A4 (en) * | 2019-08-02 | 2023-08-09 | Ajinomoto Co., Inc. | Method for producing glycomacropeptide |
| CN113214378B (en) * | 2021-06-11 | 2023-03-24 | 新希望乳业股份有限公司 | Method for separating and extracting casein glycomacropeptide |
-
2008
- 2008-11-22 CN CN2008101623396A patent/CN101413019B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 吴疆 等.酪蛋白糖巨肽的分离纯化研究.《食品技术》.2004,(第4期),全文. * |
| 张秀媛 等.凝乳酶水解酪蛋白生产酪蛋白糖巨肽工艺条件的研究.《食品工艺科技》.2008,第29卷(第4期),171-173. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101413019A (en) | 2009-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brody | Biological activities of bovine glycomacropeptide | |
| Thomä-Worringer et al. | Health effects and technological features of caseinomacropeptide | |
| CN101413019B (en) | Preparation of casein glycomacmpepride | |
| US11582994B2 (en) | Spray-dried 3-fucosyllactose | |
| Manso et al. | κ-Casein macropeptides from cheese whey: Physicochemical, biological, nutritional, and technological features for possible uses | |
| US7939118B2 (en) | Oligosaccharide mixture | |
| CN100417329C (en) | Complete separating process for fresh liquid milk | |
| RU2012145887A (en) | PEA PROTEIN PEPTIDES WITH ANTI-Helicobacter pylori ACTIVITY | |
| CN105828830A (en) | Newly identified peptides for use in the induction of oral tolerance in young mammals | |
| CN110628859A (en) | Glycosylated oyster peptide and preparation method thereof | |
| CN110951811B (en) | Glycosylated royal jelly antioxidant peptide and preparation method thereof | |
| CN103509103B (en) | Modified alpha-lactalbumin and preparation method and application thereof, and functional food | |
| JP2023073244A (en) | Intestinal environment improvement composition and method for manufacturing the same | |
| KR910008798B1 (en) | Process for preparing antibacterial composition and its active constituents | |
| TW201443079A (en) | Activating adiponectin by casein hydrolysate | |
| Recio et al. | Glycosylated dairy components: their roles in nature and ways to make use of their biofunctionality in dairy products | |
| CN114601014B (en) | Preparation method of casein micelle concentrated solution with high thermal stability and low viscosity | |
| CN115191488A (en) | Formula milk powder for improving immunity of children and preparation method thereof | |
| JP3207647B2 (en) | Immunostimulants that promote production of IgG and IgM class antibodies | |
| MX2010009430A (en) | Oligosaccharide ingredient. | |
| AU2019100971A4 (en) | Lactoferrin and sialic acid-modulated milk powder and preparation method thereof | |
| KR102686345B1 (en) | A complex peptide composition containing hydrolyzate of silk and whey protein as an active ingredient and excellent in promoting calcium absorption, and a method for manufacturing the same | |
| JP3789146B2 (en) | Oligosaccharide-containing nutritional composition | |
| AU2021107484A4 (en) | A novel nonasaccharide structure isolated from gaddi sheep’s milk | |
| Perotti et al. | Biomolecules Derived from Whey: Strategies for Production and Biological Properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110831 Termination date: 20131122 |